ResultsIQ

ResultsIQ › Latest results › CORONA Remedies Limited

CORONA Remedies Limited Q2 FY27 results deck summary

NSE: CORONA · BSE: 544644

Results deck of 30 Oct 2026, summarised by AI from the filing.

Q2 FY27 revenue rose 22.2% to ₹441.2 cr and PAT 15.3% to ₹60.3 cr, with India at 97.1% of H1 FY27 revenue.

Key takeaways

  1. No guidance The presentation gives no revenue, margin or PAT guidance for FY27 or beyond; it only sets out qualitative growth strategies.
  2. PAT margin Q2 FY27 PAT margin fell to 13.7% from 14.5% on higher depreciation and amortisation for newly commissioned facilities and brand acquisition.
  3. Brand concentration The top 5 brands account for about 36% and the top 10 about 53% of revenue.

Original filing on BSE

CORONA Remedies Limited Q2 FY27 results

As filed: Revenue ₹441 cr, EBITDA ₹96.0 cr, PAT ₹60.2 cr, EBITDA margin 21.8%.

Not scored. No result for the same quarter last year.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹422 cr, EBITDA ₹93.1 cr, PAT ₹60.1 cr, EBITDA margin 22.1%. Not scored. No result for the same quarter last year. Share price after the results: −0.9% in 28 days (Nifty 500: +0.3%).
  • Q4 FY26: Revenue ₹353 cr, EBITDA ₹62.0 cr, PAT ₹45.1 cr, EBITDA margin 17.6%. Not scored. No result for the same quarter last year. Share price after the results: −1.2% in 30 days (Nifty 500: −2.5%).
  • Q3 FY26: Revenue ₹342 cr, EBITDA ₹83.2 cr, PAT ₹41.3 cr, EBITDA margin 24.3%. Not scored. No result for the same quarter last year. Share price after the results: +5.9% in 30 days (Nifty 500: −1.9%).

Past price moves after results do not indicate future moves. Not a recommendation.

CORONA Remedies Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.